The authors intended to perform a longitudinal [11C]UCB-J PET on these AD mice to measure the treatment effects of saracatinib, an inhibitor of the tyrosine kinase Fyn which is believed to be useful in AD treatment. Here, FYN is linked to Alzheimer disease.